Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S Specifies FY 2013 Sales Growth Guidance, Confirms FY 2013 Operating Profit Guidance and Lowers FY 2013 Net Income Guidance


Wednesday, 1 May 2013 01:30am EDT 

Novo Nordisk A/S announced that for the fiscal year 2013, sales growth measured in local currencies is now expected to be between 9% and 11%, operating profit growth measured in local currencies is still expected to be around 10%, and net income is expected to amount to approximately DKK 900 million. Previously, the Company expected sales growth of between 8% and 11% and net income of approximately DKK 1,400 million. For the fiscal year 2012, the Company reported revenue of DKK 78,026.00 million and operating profit of DKK 29,474.00 million. 

Company Quote

49.03
0.56 +1.16%
18 Sep 2014